Table 4:
Functional Outcomes After TAVI or SAVR in US CoreValve Trial, As-Treated Analysisa
| Author, Year | NYHA Functional Class I/II Among Survivors, % | Quality of Life, Mean (SD) | |||
|---|---|---|---|---|---|
| KCCQ Summary | SF-12 Physical | SF-12 Mental | EQ-5D Utility | ||
|
Baseline Adams et al, 201421 Arnold et al, 201533 Reardon et al, 201534 |
TAVI: 16.9 SAVR: 18.2 |
Iliofemoral TAVI: 45.9 (23.6) SAVR: 46 (22.4) Non-iliofemoral TAVI: 51.5 (22.1) SAVR: 51.2 (21.0) |
Iliofemoral TAVI: 30.6 (9.0) SAVR: 30.7 (8.4) Non-iliofemoral TAVI: 31.4 (10.1) SAVR: 32.8 (9.0) |
Iliofemoral TAVI: 47.0 (12.3) SAVR: 48.7 (11.6) Non-iliofemoral TAVI: 49.5 (10.5) SAVR: 46.8 (11.7) |
Iliofemoral TAVI: 0.73 (0.2) SAVR: 0.73 (0.17) Non-iliofemoral TAVI: 0.76 (0.14) SAVR: 0.72 (0.21) |
| Mean Change From Baseline (95% CI) | |||||
|
30 days Adams et al, 201421 Arnold et al, 201533 Reardon et al, 201534 |
TAVI: 86.2 SAVR: 76.5 |
Iliofemoral TAVI: 21.6 (17.7–25.5) SAVR: 3.5 (−1.0 to 7.9) Non-iliofemoral TAVI: 3.3 (−7.3 to 13.9) SAVR: 5.4 (−6.2 to 17.0) |
Iliofemoral TAVI: 5.4 (4.0–6.9) SAVR: 0.0 (−1.7 to 1.7) Non-iliofemoral TAVI: 1.7 (−2.4 to 5.8) SAVR: −1.0 (−5.7 to 3.7) |
Iliofemoral TAVI: 3.5 (1.7–5.4) SAVR: −2.9 (−5.1 to −0.7) Non-iliofemoral TAVI: −2.8 (−8.1 to 2.4) SAVR: 0.4 (−6.2 to 7.0) |
Iliofemoral TAVI: 0.055 (0.024–0.087) SAVR: −0.073 (−0.116 to −0.033) Non-iliofemoral TAVI: −0.082 (−0.178 to 0.014) SAVR: −0.072 (−0.171 to 0.027) |
|
1 year Adams et al, 201421 Arnold et al, 201533 Reardon et al, 201534 |
TAVI: 94.5 SAVR: 93.2 |
Iliofemoral TAVI: 24.0 (20.6–27.5) SAVR: 21.8 (17.5–26.0) Non-iliofemoral TAVI: 18.7 (9.2–28.1) SAVR: 22.7 (14.5–30.8) |
Iliofemoral TAVI: 5.9 (4.2–7.5) SAVR: 5.1 (3.4–6.7) Non-iliofemoral TAVI: 6.6 (2.4–10.8) SAVR: 6.1 (2.1–10.2) |
Iliofemoral TAVI: 4.8 (3.0–6.5) SAVR: 2.9 (0.9–4.9) Non-iliofemoral TAVI: 3.0 (−0.6 to 6.7) SAVR: 4.8 (−0.2 to 9.9) |
Iliofemoral TAVI: 0.043 (0.015–0.071) SAVR: 0.003 (−0.029 to 0.035) Non-iliofemoral TAVI: 0.023 (−0.033 to 0.080) SAVR: 0.049 (−0.005 to 0.103) |
|
2 years Reardon et al, 201534 |
TAVI: 92.1 SAVR: 90.5 |
NA | NA | NA | NA |
Abbreviations: CI, confidence interval; EQ-5D, EuroQOL 5-dimension questionnaire; KCCQ, Kansas City Cardiomyopathy Questionnaire; NA, not available; NYHA, New York Heart Association; SD, standard deviation; SF-12, 12-item Short Form questionnaire; SAVR, surgical aortic valve replacement; TAVI, transcatheter aortic valve implantation.
a
Quality-of-life data are based on intention-to-treat analysis.